Shouyao Holdings released its 2026 interim report on August 28. First-half operating revenue was 28 million yuan, up 1,300 percent year on year. Net profit attributable to the parent narrowed from a loss of 104 million yuan in the same period last year to a loss of 61.06 million yuan. Net profit attributable to the parent after deducting non-recurring items narrowed from a loss of 114 million yuan to a loss of 67.18 million yuan. Net operating cash flow was negative 66.59 million yuan, an improvement of 41.4 percent year on year. Earnings per share were negative 0.4106 yuan. As of the end of the second quarter, total assets stood at 726 million yuan, down 8.3 percent from the end of the previous year, and net assets attributable to the parent stood at 619 million yuan, down 9.0 percent. The company's first self-developed ALK inhibitor, Conteltinib granules, received marketing approval on June 11, 2026, marking the company's transition from the research and development stage to the commercialization stage. A product developed in cooperation with Chia Tai Tianqing also obtained marketing authorization. In addition, the registration review of SY-5007 made important progress, with pivotal Phase III study data presented at the 2026 ASCO annual meeting. Two registration studies for the third-generation ALK inhibitor SY-3505 are also advancing.
Shouyao Holdings (Beijing) Co. Ltd. AFirst-half net loss narrowed to 61.06 million yuan from 104 million yuan a year earlier, with revenue up 1,300% year on year.
